Brett L Garrick

Title: Brett L Garrick: Innovator in Protease Inhibitor Peptides

Introduction

Brett L Garrick is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of biochemistry, particularly in the development of protease inhibitor peptides. With a total of four patents to his name, Garrick's work has the potential to impact clinical practices significantly.

Latest Patents

Garrick's latest patents focus on protease inhibitor peptides, specifically analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein. These analogues bind to and inhibit the activity of serine proteases, including kallikrein, plasmin, and various coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. The pharmaceutical compositions containing these KPI analogues are designed to ameliorate and treat clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Additionally, his patents provide nucleic acid sequences encoding these analogues and systems for the expression of the peptides.

Career Highlights

Throughout his career, Garrick has worked with prominent companies in the biotechnology sector, including Scios Inc. and Scios Nova, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field of protease inhibitors.

Collaborations

Garrick has collaborated with notable colleagues, including R Tyler White and Deborah Damm. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

Brett L Garrick is a distinguished inventor whose work on protease inhibitor peptides holds promise for advancing medical treatments. His contributions to the field are noteworthy and reflect his commitment to innovation in biochemistry.